95% CI	95% confidence interval
%	percent
AUC	area under the curve
CCND1	cyclin D1
CLIA	clinical laboratory improvement amendments
DNA	deoxyribonucleic acid
ER	estrogen receptor
ERBB2/Her2	erb-B2 receptor tyrosine kinase 2
FAC	fluorouracil, doxorubicin, cyclophosphamide
FDA	Food and Drug Administration
FGFR1	fibroblast growth factor receptor 1
HIV/AIDS	human immunodeficiency virus/acquired immunodeficiency syndrome
IC50	half-maximal inhibitory concentration
N	number
NCI	National Cancer Institute
PEComa	perivascular epithelioid cell tumor
PR	progesterone receptor
PRKDC	protein kinase DNA-activated catalytic polypeptide
PTEN	phosphatase and tensin homolog
RECIST	response evaluation criteria in solid tumors
RNA	ribonucleic acid
ROC	receiver operating characteristic
TTF	time-to-treatment failure